Global and Regional Drug Screening

Drug Screening Comprehensive Study by Type (Immunoassay Analyzer, Chromatography, Breathalyzer, Rapid Test Device, Assay Kits), Sample Type (Urine Samples, Breath Samples, Oral Fluid Samples, Hair Samples, Other Samples), End User (Workplace, Criminal Justice Systems and Law Enforcement Agencies, Drug Treatment Centers, Pain Management Centers, Schools and Colleges, Hospitals, Individual Users, Drug Testing Laboratories) Players and Region - Global Market Outlook to 2026

Drug Screening Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 9.45%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Drug screening is a method in which potential drugs are identified as well as optimized before selection of a candidate drug in order to progress to clinical trials. It is a cost-effective method to quickly review all samples. It is highly reactive, but not highly selective. It analyses various biological samples, namely hair, blood, & urine in order to diagnose the presence of drug abuse. It is used to determine, whether the person is the influences of the drug at a certain point of time. The urine sample is mostly used for screening due to its low cost as well as result reliability. Drug screening is a two-step process which includes initial test and a confirmatory test. Increase in alcohol consumption among youth and elderly population, overuse of prescribed drugs, the rise in use of narcotics and illicit drugs are some of the major drivers which are propelling the growth of the market.The research analyst at AMA estimates Drug Screening market to grow at a compounded annual growth rate of 9.45%

Segment Analysis
AMA Research have segmented the market of Global Drug Screening market by Type, Application and Region. On the basis of Type, Breathalyzer are dominating the market in the year 2020

On the basis of geography, the market of Drug Screening has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2020. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Market Trend
Technology Advancement of the Drug Screening and Increasing Usage in Oral Fluid Testing across the World

Market Drivers
Growing Drug & Alcohol Consumption and Enforcement of Stringent Laws Mandating Drug as well as Alcohol Testing and Presence of Government Funding in Major Markets and Regulatory Approvals & Product Launches and Services

Opportunities
Increasing Demand from Emerging Economies Such As India, China, and Others

Restraints
  • Issue related to Ban on Alcohol Consumption in Several Islamic Countries and Prohibition of Workplace Drug Testing in Some Countries


In addition to the aforementioned factor, Growing Drug & Alcohol Consumption and Enforcement of Stringent Laws Mandating Drug as well as Alcohol Testing is expected to propel the growth of the market over the forecast period.

The key Players profiled in the study are Alere (United States), Thermo Fisher (United States), Drägerwerk (Germany), OraSure (United States), Alfa Scientific Designs (United States), Lifeloc (United States), MPD, Inc. (United States), Premier Biotech (United States), Shimadzu (Japan), and Siemens Healthineers (United States). A lot of United States players are profiled in the research study indicating a strong market dependence.

Report Objectives / Segmentation Covered

By Type
  • Immunoassay Analyzer
  • Chromatography
  • Breathalyzer
  • Rapid Test Device
  • Assay Kits
By Sample Type
  • Urine Samples
  • Breath Samples
  • Oral Fluid Samples
  • Hair Samples
  • Other Samples

By End User
  • Workplace
  • Criminal Justice Systems and Law Enforcement Agencies
  • Drug Treatment Centers
  • Pain Management Centers
  • Schools and Colleges
  • Hospitals
  • Individual Users
  • Drug Testing Laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Drug & Alcohol Consumption and Enforcement of Stringent Laws Mandating Drug as well as Alcohol Testing
      • 3.2.2. Presence of Government Funding in Major Markets and Regulatory Approvals & Product Launches and Services
    • 3.3. Market Challenges
      • 3.3.1. The problem regarding the Accuracy and Specificity Concerns Related to Breathalyzers
    • 3.4. Market Trends
      • 3.4.1. Technology Advancement of the Drug Screening and Increasing Usage in Oral Fluid Testing across the World
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drug Screening, by Type, Sample Type, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Drug Screening (Value)
      • 5.2.1. Global Drug Screening by: Type (Value)
        • 5.2.1.1. Immunoassay Analyzer
        • 5.2.1.2. Chromatography
        • 5.2.1.3. Breathalyzer
        • 5.2.1.4. Rapid Test Device
        • 5.2.1.5. Assay Kits
      • 5.2.2. Global Drug Screening by: Sample Type (Value)
        • 5.2.2.1. Urine Samples
        • 5.2.2.2. Breath Samples
        • 5.2.2.3. Oral Fluid Samples
        • 5.2.2.4. Hair Samples
        • 5.2.2.5. Other Samples
      • 5.2.3. Global Drug Screening by: End User (Value)
        • 5.2.3.1. Workplace
        • 5.2.3.2. Criminal Justice Systems and Law Enforcement Agencies
        • 5.2.3.3. Drug Treatment Centers
        • 5.2.3.4. Pain Management Centers
        • 5.2.3.5. Schools and Colleges
        • 5.2.3.6. Hospitals
        • 5.2.3.7. Individual Users
        • 5.2.3.8. Drug Testing Laboratories
      • 5.2.4. Global Drug Screening Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Drug Screening (Volume)
      • 5.3.1. Global Drug Screening by: Type (Volume)
        • 5.3.1.1. Immunoassay Analyzer
        • 5.3.1.2. Chromatography
        • 5.3.1.3. Breathalyzer
        • 5.3.1.4. Rapid Test Device
        • 5.3.1.5. Assay Kits
      • 5.3.2. Global Drug Screening by: Sample Type (Volume)
        • 5.3.2.1. Urine Samples
        • 5.3.2.2. Breath Samples
        • 5.3.2.3. Oral Fluid Samples
        • 5.3.2.4. Hair Samples
        • 5.3.2.5. Other Samples
      • 5.3.3. Global Drug Screening by: End User (Volume)
        • 5.3.3.1. Workplace
        • 5.3.3.2. Criminal Justice Systems and Law Enforcement Agencies
        • 5.3.3.3. Drug Treatment Centers
        • 5.3.3.4. Pain Management Centers
        • 5.3.3.5. Schools and Colleges
        • 5.3.3.6. Hospitals
        • 5.3.3.7. Individual Users
        • 5.3.3.8. Drug Testing Laboratories
      • 5.3.4. Global Drug Screening Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Drug Screening (Price)
      • 5.4.1. Global Drug Screening by: Type (Price)
  • 6. Drug Screening: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alere (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Drägerwerk (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. OraSure (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Alfa Scientific Designs (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lifeloc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MPD, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Premier Biotech (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shimadzu (Japan),
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Siemens Healthineers (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drug Screening Sale, by Type, Sample Type, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Drug Screening (Value)
      • 7.2.1. Global Drug Screening by: Type (Value)
        • 7.2.1.1. Immunoassay Analyzer
        • 7.2.1.2. Chromatography
        • 7.2.1.3. Breathalyzer
        • 7.2.1.4. Rapid Test Device
        • 7.2.1.5. Assay Kits
      • 7.2.2. Global Drug Screening by: Sample Type (Value)
        • 7.2.2.1. Urine Samples
        • 7.2.2.2. Breath Samples
        • 7.2.2.3. Oral Fluid Samples
        • 7.2.2.4. Hair Samples
        • 7.2.2.5. Other Samples
      • 7.2.3. Global Drug Screening by: End User (Value)
        • 7.2.3.1. Workplace
        • 7.2.3.2. Criminal Justice Systems and Law Enforcement Agencies
        • 7.2.3.3. Drug Treatment Centers
        • 7.2.3.4. Pain Management Centers
        • 7.2.3.5. Schools and Colleges
        • 7.2.3.6. Hospitals
        • 7.2.3.7. Individual Users
        • 7.2.3.8. Drug Testing Laboratories
      • 7.2.4. Global Drug Screening Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Drug Screening (Volume)
      • 7.3.1. Global Drug Screening by: Type (Volume)
        • 7.3.1.1. Immunoassay Analyzer
        • 7.3.1.2. Chromatography
        • 7.3.1.3. Breathalyzer
        • 7.3.1.4. Rapid Test Device
        • 7.3.1.5. Assay Kits
      • 7.3.2. Global Drug Screening by: Sample Type (Volume)
        • 7.3.2.1. Urine Samples
        • 7.3.2.2. Breath Samples
        • 7.3.2.3. Oral Fluid Samples
        • 7.3.2.4. Hair Samples
        • 7.3.2.5. Other Samples
      • 7.3.3. Global Drug Screening by: End User (Volume)
        • 7.3.3.1. Workplace
        • 7.3.3.2. Criminal Justice Systems and Law Enforcement Agencies
        • 7.3.3.3. Drug Treatment Centers
        • 7.3.3.4. Pain Management Centers
        • 7.3.3.5. Schools and Colleges
        • 7.3.3.6. Hospitals
        • 7.3.3.7. Individual Users
        • 7.3.3.8. Drug Testing Laboratories
      • 7.3.4. Global Drug Screening Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Drug Screening (Price)
      • 7.4.1. Global Drug Screening by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drug Screening: by Type(USD Million)
  • Table 2. Drug Screening Immunoassay Analyzer , by Region USD Million (2015-2020)
  • Table 3. Drug Screening Chromatography , by Region USD Million (2015-2020)
  • Table 4. Drug Screening Breathalyzer , by Region USD Million (2015-2020)
  • Table 5. Drug Screening Rapid Test Device , by Region USD Million (2015-2020)
  • Table 6. Drug Screening Assay Kits , by Region USD Million (2015-2020)
  • Table 7. Drug Screening: by Sample Type(USD Million)
  • Table 8. Drug Screening Urine Samples , by Region USD Million (2015-2020)
  • Table 9. Drug Screening Breath Samples , by Region USD Million (2015-2020)
  • Table 10. Drug Screening Oral Fluid Samples , by Region USD Million (2015-2020)
  • Table 11. Drug Screening Hair Samples , by Region USD Million (2015-2020)
  • Table 12. Drug Screening Other Samples , by Region USD Million (2015-2020)
  • Table 13. Drug Screening: by End User(USD Million)
  • Table 14. Drug Screening Workplace , by Region USD Million (2015-2020)
  • Table 15. Drug Screening Criminal Justice Systems and Law Enforcement Agencies , by Region USD Million (2015-2020)
  • Table 16. Drug Screening Drug Treatment Centers , by Region USD Million (2015-2020)
  • Table 17. Drug Screening Pain Management Centers , by Region USD Million (2015-2020)
  • Table 18. Drug Screening Schools and Colleges , by Region USD Million (2015-2020)
  • Table 19. Drug Screening Hospitals , by Region USD Million (2015-2020)
  • Table 20. Drug Screening Individual Users , by Region USD Million (2015-2020)
  • Table 21. Drug Screening Drug Testing Laboratories , by Region USD Million (2015-2020)
  • Table 22. South America Drug Screening, by Country USD Million (2015-2020)
  • Table 23. South America Drug Screening, by Type USD Million (2015-2020)
  • Table 24. South America Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 25. South America Drug Screening, by End User USD Million (2015-2020)
  • Table 26. Brazil Drug Screening, by Type USD Million (2015-2020)
  • Table 27. Brazil Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 28. Brazil Drug Screening, by End User USD Million (2015-2020)
  • Table 29. Argentina Drug Screening, by Type USD Million (2015-2020)
  • Table 30. Argentina Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 31. Argentina Drug Screening, by End User USD Million (2015-2020)
  • Table 32. Rest of South America Drug Screening, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 34. Rest of South America Drug Screening, by End User USD Million (2015-2020)
  • Table 35. Asia Pacific Drug Screening, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Drug Screening, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 38. Asia Pacific Drug Screening, by End User USD Million (2015-2020)
  • Table 39. China Drug Screening, by Type USD Million (2015-2020)
  • Table 40. China Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 41. China Drug Screening, by End User USD Million (2015-2020)
  • Table 42. Japan Drug Screening, by Type USD Million (2015-2020)
  • Table 43. Japan Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 44. Japan Drug Screening, by End User USD Million (2015-2020)
  • Table 45. India Drug Screening, by Type USD Million (2015-2020)
  • Table 46. India Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 47. India Drug Screening, by End User USD Million (2015-2020)
  • Table 48. South Korea Drug Screening, by Type USD Million (2015-2020)
  • Table 49. South Korea Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 50. South Korea Drug Screening, by End User USD Million (2015-2020)
  • Table 51. Taiwan Drug Screening, by Type USD Million (2015-2020)
  • Table 52. Taiwan Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 53. Taiwan Drug Screening, by End User USD Million (2015-2020)
  • Table 54. Australia Drug Screening, by Type USD Million (2015-2020)
  • Table 55. Australia Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 56. Australia Drug Screening, by End User USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Drug Screening, by Type USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Drug Screening, by End User USD Million (2015-2020)
  • Table 60. Europe Drug Screening, by Country USD Million (2015-2020)
  • Table 61. Europe Drug Screening, by Type USD Million (2015-2020)
  • Table 62. Europe Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 63. Europe Drug Screening, by End User USD Million (2015-2020)
  • Table 64. Germany Drug Screening, by Type USD Million (2015-2020)
  • Table 65. Germany Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 66. Germany Drug Screening, by End User USD Million (2015-2020)
  • Table 67. France Drug Screening, by Type USD Million (2015-2020)
  • Table 68. France Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 69. France Drug Screening, by End User USD Million (2015-2020)
  • Table 70. Italy Drug Screening, by Type USD Million (2015-2020)
  • Table 71. Italy Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 72. Italy Drug Screening, by End User USD Million (2015-2020)
  • Table 73. United Kingdom Drug Screening, by Type USD Million (2015-2020)
  • Table 74. United Kingdom Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 75. United Kingdom Drug Screening, by End User USD Million (2015-2020)
  • Table 76. Netherlands Drug Screening, by Type USD Million (2015-2020)
  • Table 77. Netherlands Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 78. Netherlands Drug Screening, by End User USD Million (2015-2020)
  • Table 79. Rest of Europe Drug Screening, by Type USD Million (2015-2020)
  • Table 80. Rest of Europe Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 81. Rest of Europe Drug Screening, by End User USD Million (2015-2020)
  • Table 82. MEA Drug Screening, by Country USD Million (2015-2020)
  • Table 83. MEA Drug Screening, by Type USD Million (2015-2020)
  • Table 84. MEA Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 85. MEA Drug Screening, by End User USD Million (2015-2020)
  • Table 86. Middle East Drug Screening, by Type USD Million (2015-2020)
  • Table 87. Middle East Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 88. Middle East Drug Screening, by End User USD Million (2015-2020)
  • Table 89. Africa Drug Screening, by Type USD Million (2015-2020)
  • Table 90. Africa Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 91. Africa Drug Screening, by End User USD Million (2015-2020)
  • Table 92. North America Drug Screening, by Country USD Million (2015-2020)
  • Table 93. North America Drug Screening, by Type USD Million (2015-2020)
  • Table 94. North America Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 95. North America Drug Screening, by End User USD Million (2015-2020)
  • Table 96. United States Drug Screening, by Type USD Million (2015-2020)
  • Table 97. United States Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 98. United States Drug Screening, by End User USD Million (2015-2020)
  • Table 99. Canada Drug Screening, by Type USD Million (2015-2020)
  • Table 100. Canada Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 101. Canada Drug Screening, by End User USD Million (2015-2020)
  • Table 102. Mexico Drug Screening, by Type USD Million (2015-2020)
  • Table 103. Mexico Drug Screening, by Sample Type USD Million (2015-2020)
  • Table 104. Mexico Drug Screening, by End User USD Million (2015-2020)
  • Table 105. Drug Screening Sales: by Type(k Units)
  • Table 106. Drug Screening Sales Immunoassay Analyzer , by Region k Units (2015-2020)
  • Table 107. Drug Screening Sales Chromatography , by Region k Units (2015-2020)
  • Table 108. Drug Screening Sales Breathalyzer , by Region k Units (2015-2020)
  • Table 109. Drug Screening Sales Rapid Test Device , by Region k Units (2015-2020)
  • Table 110. Drug Screening Sales Assay Kits , by Region k Units (2015-2020)
  • Table 111. Drug Screening Sales: by Sample Type(k Units)
  • Table 112. Drug Screening Sales Urine Samples , by Region k Units (2015-2020)
  • Table 113. Drug Screening Sales Breath Samples , by Region k Units (2015-2020)
  • Table 114. Drug Screening Sales Oral Fluid Samples , by Region k Units (2015-2020)
  • Table 115. Drug Screening Sales Hair Samples , by Region k Units (2015-2020)
  • Table 116. Drug Screening Sales Other Samples , by Region k Units (2015-2020)
  • Table 117. Drug Screening Sales: by End User(k Units)
  • Table 118. Drug Screening Sales Workplace , by Region k Units (2015-2020)
  • Table 119. Drug Screening Sales Criminal Justice Systems and Law Enforcement Agencies , by Region k Units (2015-2020)
  • Table 120. Drug Screening Sales Drug Treatment Centers , by Region k Units (2015-2020)
  • Table 121. Drug Screening Sales Pain Management Centers , by Region k Units (2015-2020)
  • Table 122. Drug Screening Sales Schools and Colleges , by Region k Units (2015-2020)
  • Table 123. Drug Screening Sales Hospitals , by Region k Units (2015-2020)
  • Table 124. Drug Screening Sales Individual Users , by Region k Units (2015-2020)
  • Table 125. Drug Screening Sales Drug Testing Laboratories , by Region k Units (2015-2020)
  • Table 126. South America Drug Screening Sales, by Country k Units (2015-2020)
  • Table 127. South America Drug Screening Sales, by Type k Units (2015-2020)
  • Table 128. South America Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 129. South America Drug Screening Sales, by End User k Units (2015-2020)
  • Table 130. Brazil Drug Screening Sales, by Type k Units (2015-2020)
  • Table 131. Brazil Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 132. Brazil Drug Screening Sales, by End User k Units (2015-2020)
  • Table 133. Argentina Drug Screening Sales, by Type k Units (2015-2020)
  • Table 134. Argentina Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 135. Argentina Drug Screening Sales, by End User k Units (2015-2020)
  • Table 136. Rest of South America Drug Screening Sales, by Type k Units (2015-2020)
  • Table 137. Rest of South America Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 138. Rest of South America Drug Screening Sales, by End User k Units (2015-2020)
  • Table 139. Asia Pacific Drug Screening Sales, by Country k Units (2015-2020)
  • Table 140. Asia Pacific Drug Screening Sales, by Type k Units (2015-2020)
  • Table 141. Asia Pacific Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 142. Asia Pacific Drug Screening Sales, by End User k Units (2015-2020)
  • Table 143. China Drug Screening Sales, by Type k Units (2015-2020)
  • Table 144. China Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 145. China Drug Screening Sales, by End User k Units (2015-2020)
  • Table 146. Japan Drug Screening Sales, by Type k Units (2015-2020)
  • Table 147. Japan Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 148. Japan Drug Screening Sales, by End User k Units (2015-2020)
  • Table 149. India Drug Screening Sales, by Type k Units (2015-2020)
  • Table 150. India Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 151. India Drug Screening Sales, by End User k Units (2015-2020)
  • Table 152. South Korea Drug Screening Sales, by Type k Units (2015-2020)
  • Table 153. South Korea Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 154. South Korea Drug Screening Sales, by End User k Units (2015-2020)
  • Table 155. Taiwan Drug Screening Sales, by Type k Units (2015-2020)
  • Table 156. Taiwan Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 157. Taiwan Drug Screening Sales, by End User k Units (2015-2020)
  • Table 158. Australia Drug Screening Sales, by Type k Units (2015-2020)
  • Table 159. Australia Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 160. Australia Drug Screening Sales, by End User k Units (2015-2020)
  • Table 161. Rest of Asia-Pacific Drug Screening Sales, by Type k Units (2015-2020)
  • Table 162. Rest of Asia-Pacific Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 163. Rest of Asia-Pacific Drug Screening Sales, by End User k Units (2015-2020)
  • Table 164. Europe Drug Screening Sales, by Country k Units (2015-2020)
  • Table 165. Europe Drug Screening Sales, by Type k Units (2015-2020)
  • Table 166. Europe Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 167. Europe Drug Screening Sales, by End User k Units (2015-2020)
  • Table 168. Germany Drug Screening Sales, by Type k Units (2015-2020)
  • Table 169. Germany Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 170. Germany Drug Screening Sales, by End User k Units (2015-2020)
  • Table 171. France Drug Screening Sales, by Type k Units (2015-2020)
  • Table 172. France Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 173. France Drug Screening Sales, by End User k Units (2015-2020)
  • Table 174. Italy Drug Screening Sales, by Type k Units (2015-2020)
  • Table 175. Italy Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 176. Italy Drug Screening Sales, by End User k Units (2015-2020)
  • Table 177. United Kingdom Drug Screening Sales, by Type k Units (2015-2020)
  • Table 178. United Kingdom Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 179. United Kingdom Drug Screening Sales, by End User k Units (2015-2020)
  • Table 180. Netherlands Drug Screening Sales, by Type k Units (2015-2020)
  • Table 181. Netherlands Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 182. Netherlands Drug Screening Sales, by End User k Units (2015-2020)
  • Table 183. Rest of Europe Drug Screening Sales, by Type k Units (2015-2020)
  • Table 184. Rest of Europe Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 185. Rest of Europe Drug Screening Sales, by End User k Units (2015-2020)
  • Table 186. MEA Drug Screening Sales, by Country k Units (2015-2020)
  • Table 187. MEA Drug Screening Sales, by Type k Units (2015-2020)
  • Table 188. MEA Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 189. MEA Drug Screening Sales, by End User k Units (2015-2020)
  • Table 190. Middle East Drug Screening Sales, by Type k Units (2015-2020)
  • Table 191. Middle East Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 192. Middle East Drug Screening Sales, by End User k Units (2015-2020)
  • Table 193. Africa Drug Screening Sales, by Type k Units (2015-2020)
  • Table 194. Africa Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 195. Africa Drug Screening Sales, by End User k Units (2015-2020)
  • Table 196. North America Drug Screening Sales, by Country k Units (2015-2020)
  • Table 197. North America Drug Screening Sales, by Type k Units (2015-2020)
  • Table 198. North America Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 199. North America Drug Screening Sales, by End User k Units (2015-2020)
  • Table 200. United States Drug Screening Sales, by Type k Units (2015-2020)
  • Table 201. United States Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 202. United States Drug Screening Sales, by End User k Units (2015-2020)
  • Table 203. Canada Drug Screening Sales, by Type k Units (2015-2020)
  • Table 204. Canada Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 205. Canada Drug Screening Sales, by End User k Units (2015-2020)
  • Table 206. Mexico Drug Screening Sales, by Type k Units (2015-2020)
  • Table 207. Mexico Drug Screening Sales, by Sample Type k Units (2015-2020)
  • Table 208. Mexico Drug Screening Sales, by End User k Units (2015-2020)
  • Table 209. Drug Screening: by Type(USD/Units)
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Company Basic Information, Sales Area and Its Competitors
  • Table 214. Company Basic Information, Sales Area and Its Competitors
  • Table 215. Company Basic Information, Sales Area and Its Competitors
  • Table 216. Company Basic Information, Sales Area and Its Competitors
  • Table 217. Company Basic Information, Sales Area and Its Competitors
  • Table 218. Company Basic Information, Sales Area and Its Competitors
  • Table 219. Company Basic Information, Sales Area and Its Competitors
  • Table 220. Drug Screening: by Type(USD Million)
  • Table 221. Drug Screening Immunoassay Analyzer , by Region USD Million (2021-2026)
  • Table 222. Drug Screening Chromatography , by Region USD Million (2021-2026)
  • Table 223. Drug Screening Breathalyzer , by Region USD Million (2021-2026)
  • Table 224. Drug Screening Rapid Test Device , by Region USD Million (2021-2026)
  • Table 225. Drug Screening Assay Kits , by Region USD Million (2021-2026)
  • Table 226. Drug Screening: by Sample Type(USD Million)
  • Table 227. Drug Screening Urine Samples , by Region USD Million (2021-2026)
  • Table 228. Drug Screening Breath Samples , by Region USD Million (2021-2026)
  • Table 229. Drug Screening Oral Fluid Samples , by Region USD Million (2021-2026)
  • Table 230. Drug Screening Hair Samples , by Region USD Million (2021-2026)
  • Table 231. Drug Screening Other Samples , by Region USD Million (2021-2026)
  • Table 232. Drug Screening: by End User(USD Million)
  • Table 233. Drug Screening Workplace , by Region USD Million (2021-2026)
  • Table 234. Drug Screening Criminal Justice Systems and Law Enforcement Agencies , by Region USD Million (2021-2026)
  • Table 235. Drug Screening Drug Treatment Centers , by Region USD Million (2021-2026)
  • Table 236. Drug Screening Pain Management Centers , by Region USD Million (2021-2026)
  • Table 237. Drug Screening Schools and Colleges , by Region USD Million (2021-2026)
  • Table 238. Drug Screening Hospitals , by Region USD Million (2021-2026)
  • Table 239. Drug Screening Individual Users , by Region USD Million (2021-2026)
  • Table 240. Drug Screening Drug Testing Laboratories , by Region USD Million (2021-2026)
  • Table 241. South America Drug Screening, by Country USD Million (2021-2026)
  • Table 242. South America Drug Screening, by Type USD Million (2021-2026)
  • Table 243. South America Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 244. South America Drug Screening, by End User USD Million (2021-2026)
  • Table 245. Brazil Drug Screening, by Type USD Million (2021-2026)
  • Table 246. Brazil Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 247. Brazil Drug Screening, by End User USD Million (2021-2026)
  • Table 248. Argentina Drug Screening, by Type USD Million (2021-2026)
  • Table 249. Argentina Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 250. Argentina Drug Screening, by End User USD Million (2021-2026)
  • Table 251. Rest of South America Drug Screening, by Type USD Million (2021-2026)
  • Table 252. Rest of South America Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 253. Rest of South America Drug Screening, by End User USD Million (2021-2026)
  • Table 254. Asia Pacific Drug Screening, by Country USD Million (2021-2026)
  • Table 255. Asia Pacific Drug Screening, by Type USD Million (2021-2026)
  • Table 256. Asia Pacific Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 257. Asia Pacific Drug Screening, by End User USD Million (2021-2026)
  • Table 258. China Drug Screening, by Type USD Million (2021-2026)
  • Table 259. China Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 260. China Drug Screening, by End User USD Million (2021-2026)
  • Table 261. Japan Drug Screening, by Type USD Million (2021-2026)
  • Table 262. Japan Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 263. Japan Drug Screening, by End User USD Million (2021-2026)
  • Table 264. India Drug Screening, by Type USD Million (2021-2026)
  • Table 265. India Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 266. India Drug Screening, by End User USD Million (2021-2026)
  • Table 267. South Korea Drug Screening, by Type USD Million (2021-2026)
  • Table 268. South Korea Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 269. South Korea Drug Screening, by End User USD Million (2021-2026)
  • Table 270. Taiwan Drug Screening, by Type USD Million (2021-2026)
  • Table 271. Taiwan Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 272. Taiwan Drug Screening, by End User USD Million (2021-2026)
  • Table 273. Australia Drug Screening, by Type USD Million (2021-2026)
  • Table 274. Australia Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 275. Australia Drug Screening, by End User USD Million (2021-2026)
  • Table 276. Rest of Asia-Pacific Drug Screening, by Type USD Million (2021-2026)
  • Table 277. Rest of Asia-Pacific Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 278. Rest of Asia-Pacific Drug Screening, by End User USD Million (2021-2026)
  • Table 279. Europe Drug Screening, by Country USD Million (2021-2026)
  • Table 280. Europe Drug Screening, by Type USD Million (2021-2026)
  • Table 281. Europe Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 282. Europe Drug Screening, by End User USD Million (2021-2026)
  • Table 283. Germany Drug Screening, by Type USD Million (2021-2026)
  • Table 284. Germany Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 285. Germany Drug Screening, by End User USD Million (2021-2026)
  • Table 286. France Drug Screening, by Type USD Million (2021-2026)
  • Table 287. France Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 288. France Drug Screening, by End User USD Million (2021-2026)
  • Table 289. Italy Drug Screening, by Type USD Million (2021-2026)
  • Table 290. Italy Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 291. Italy Drug Screening, by End User USD Million (2021-2026)
  • Table 292. United Kingdom Drug Screening, by Type USD Million (2021-2026)
  • Table 293. United Kingdom Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 294. United Kingdom Drug Screening, by End User USD Million (2021-2026)
  • Table 295. Netherlands Drug Screening, by Type USD Million (2021-2026)
  • Table 296. Netherlands Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 297. Netherlands Drug Screening, by End User USD Million (2021-2026)
  • Table 298. Rest of Europe Drug Screening, by Type USD Million (2021-2026)
  • Table 299. Rest of Europe Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 300. Rest of Europe Drug Screening, by End User USD Million (2021-2026)
  • Table 301. MEA Drug Screening, by Country USD Million (2021-2026)
  • Table 302. MEA Drug Screening, by Type USD Million (2021-2026)
  • Table 303. MEA Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 304. MEA Drug Screening, by End User USD Million (2021-2026)
  • Table 305. Middle East Drug Screening, by Type USD Million (2021-2026)
  • Table 306. Middle East Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 307. Middle East Drug Screening, by End User USD Million (2021-2026)
  • Table 308. Africa Drug Screening, by Type USD Million (2021-2026)
  • Table 309. Africa Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 310. Africa Drug Screening, by End User USD Million (2021-2026)
  • Table 311. North America Drug Screening, by Country USD Million (2021-2026)
  • Table 312. North America Drug Screening, by Type USD Million (2021-2026)
  • Table 313. North America Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 314. North America Drug Screening, by End User USD Million (2021-2026)
  • Table 315. United States Drug Screening, by Type USD Million (2021-2026)
  • Table 316. United States Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 317. United States Drug Screening, by End User USD Million (2021-2026)
  • Table 318. Canada Drug Screening, by Type USD Million (2021-2026)
  • Table 319. Canada Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 320. Canada Drug Screening, by End User USD Million (2021-2026)
  • Table 321. Mexico Drug Screening, by Type USD Million (2021-2026)
  • Table 322. Mexico Drug Screening, by Sample Type USD Million (2021-2026)
  • Table 323. Mexico Drug Screening, by End User USD Million (2021-2026)
  • Table 324. Drug Screening Sales: by Type(k Units)
  • Table 325. Drug Screening Sales Immunoassay Analyzer , by Region k Units (2021-2026)
  • Table 326. Drug Screening Sales Chromatography , by Region k Units (2021-2026)
  • Table 327. Drug Screening Sales Breathalyzer , by Region k Units (2021-2026)
  • Table 328. Drug Screening Sales Rapid Test Device , by Region k Units (2021-2026)
  • Table 329. Drug Screening Sales Assay Kits , by Region k Units (2021-2026)
  • Table 330. Drug Screening Sales: by Sample Type(k Units)
  • Table 331. Drug Screening Sales Urine Samples , by Region k Units (2021-2026)
  • Table 332. Drug Screening Sales Breath Samples , by Region k Units (2021-2026)
  • Table 333. Drug Screening Sales Oral Fluid Samples , by Region k Units (2021-2026)
  • Table 334. Drug Screening Sales Hair Samples , by Region k Units (2021-2026)
  • Table 335. Drug Screening Sales Other Samples , by Region k Units (2021-2026)
  • Table 336. Drug Screening Sales: by End User(k Units)
  • Table 337. Drug Screening Sales Workplace , by Region k Units (2021-2026)
  • Table 338. Drug Screening Sales Criminal Justice Systems and Law Enforcement Agencies , by Region k Units (2021-2026)
  • Table 339. Drug Screening Sales Drug Treatment Centers , by Region k Units (2021-2026)
  • Table 340. Drug Screening Sales Pain Management Centers , by Region k Units (2021-2026)
  • Table 341. Drug Screening Sales Schools and Colleges , by Region k Units (2021-2026)
  • Table 342. Drug Screening Sales Hospitals , by Region k Units (2021-2026)
  • Table 343. Drug Screening Sales Individual Users , by Region k Units (2021-2026)
  • Table 344. Drug Screening Sales Drug Testing Laboratories , by Region k Units (2021-2026)
  • Table 345. South America Drug Screening Sales, by Country k Units (2021-2026)
  • Table 346. South America Drug Screening Sales, by Type k Units (2021-2026)
  • Table 347. South America Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 348. South America Drug Screening Sales, by End User k Units (2021-2026)
  • Table 349. Brazil Drug Screening Sales, by Type k Units (2021-2026)
  • Table 350. Brazil Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 351. Brazil Drug Screening Sales, by End User k Units (2021-2026)
  • Table 352. Argentina Drug Screening Sales, by Type k Units (2021-2026)
  • Table 353. Argentina Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 354. Argentina Drug Screening Sales, by End User k Units (2021-2026)
  • Table 355. Rest of South America Drug Screening Sales, by Type k Units (2021-2026)
  • Table 356. Rest of South America Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 357. Rest of South America Drug Screening Sales, by End User k Units (2021-2026)
  • Table 358. Asia Pacific Drug Screening Sales, by Country k Units (2021-2026)
  • Table 359. Asia Pacific Drug Screening Sales, by Type k Units (2021-2026)
  • Table 360. Asia Pacific Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 361. Asia Pacific Drug Screening Sales, by End User k Units (2021-2026)
  • Table 362. China Drug Screening Sales, by Type k Units (2021-2026)
  • Table 363. China Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 364. China Drug Screening Sales, by End User k Units (2021-2026)
  • Table 365. Japan Drug Screening Sales, by Type k Units (2021-2026)
  • Table 366. Japan Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 367. Japan Drug Screening Sales, by End User k Units (2021-2026)
  • Table 368. India Drug Screening Sales, by Type k Units (2021-2026)
  • Table 369. India Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 370. India Drug Screening Sales, by End User k Units (2021-2026)
  • Table 371. South Korea Drug Screening Sales, by Type k Units (2021-2026)
  • Table 372. South Korea Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 373. South Korea Drug Screening Sales, by End User k Units (2021-2026)
  • Table 374. Taiwan Drug Screening Sales, by Type k Units (2021-2026)
  • Table 375. Taiwan Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 376. Taiwan Drug Screening Sales, by End User k Units (2021-2026)
  • Table 377. Australia Drug Screening Sales, by Type k Units (2021-2026)
  • Table 378. Australia Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 379. Australia Drug Screening Sales, by End User k Units (2021-2026)
  • Table 380. Rest of Asia-Pacific Drug Screening Sales, by Type k Units (2021-2026)
  • Table 381. Rest of Asia-Pacific Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 382. Rest of Asia-Pacific Drug Screening Sales, by End User k Units (2021-2026)
  • Table 383. Europe Drug Screening Sales, by Country k Units (2021-2026)
  • Table 384. Europe Drug Screening Sales, by Type k Units (2021-2026)
  • Table 385. Europe Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 386. Europe Drug Screening Sales, by End User k Units (2021-2026)
  • Table 387. Germany Drug Screening Sales, by Type k Units (2021-2026)
  • Table 388. Germany Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 389. Germany Drug Screening Sales, by End User k Units (2021-2026)
  • Table 390. France Drug Screening Sales, by Type k Units (2021-2026)
  • Table 391. France Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 392. France Drug Screening Sales, by End User k Units (2021-2026)
  • Table 393. Italy Drug Screening Sales, by Type k Units (2021-2026)
  • Table 394. Italy Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 395. Italy Drug Screening Sales, by End User k Units (2021-2026)
  • Table 396. United Kingdom Drug Screening Sales, by Type k Units (2021-2026)
  • Table 397. United Kingdom Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 398. United Kingdom Drug Screening Sales, by End User k Units (2021-2026)
  • Table 399. Netherlands Drug Screening Sales, by Type k Units (2021-2026)
  • Table 400. Netherlands Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 401. Netherlands Drug Screening Sales, by End User k Units (2021-2026)
  • Table 402. Rest of Europe Drug Screening Sales, by Type k Units (2021-2026)
  • Table 403. Rest of Europe Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 404. Rest of Europe Drug Screening Sales, by End User k Units (2021-2026)
  • Table 405. MEA Drug Screening Sales, by Country k Units (2021-2026)
  • Table 406. MEA Drug Screening Sales, by Type k Units (2021-2026)
  • Table 407. MEA Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 408. MEA Drug Screening Sales, by End User k Units (2021-2026)
  • Table 409. Middle East Drug Screening Sales, by Type k Units (2021-2026)
  • Table 410. Middle East Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 411. Middle East Drug Screening Sales, by End User k Units (2021-2026)
  • Table 412. Africa Drug Screening Sales, by Type k Units (2021-2026)
  • Table 413. Africa Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 414. Africa Drug Screening Sales, by End User k Units (2021-2026)
  • Table 415. North America Drug Screening Sales, by Country k Units (2021-2026)
  • Table 416. North America Drug Screening Sales, by Type k Units (2021-2026)
  • Table 417. North America Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 418. North America Drug Screening Sales, by End User k Units (2021-2026)
  • Table 419. United States Drug Screening Sales, by Type k Units (2021-2026)
  • Table 420. United States Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 421. United States Drug Screening Sales, by End User k Units (2021-2026)
  • Table 422. Canada Drug Screening Sales, by Type k Units (2021-2026)
  • Table 423. Canada Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 424. Canada Drug Screening Sales, by End User k Units (2021-2026)
  • Table 425. Mexico Drug Screening Sales, by Type k Units (2021-2026)
  • Table 426. Mexico Drug Screening Sales, by Sample Type k Units (2021-2026)
  • Table 427. Mexico Drug Screening Sales, by End User k Units (2021-2026)
  • Table 428. Drug Screening: by Type(USD/Units)
  • Table 429. Research Programs/Design for This Report
  • Table 430. Key Data Information from Secondary Sources
  • Table 431. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drug Screening: by Type USD Million (2015-2020)
  • Figure 5. Global Drug Screening: by Sample Type USD Million (2015-2020)
  • Figure 6. Global Drug Screening: by End User USD Million (2015-2020)
  • Figure 7. South America Drug Screening Share (%), by Country
  • Figure 8. Asia Pacific Drug Screening Share (%), by Country
  • Figure 9. Europe Drug Screening Share (%), by Country
  • Figure 10. MEA Drug Screening Share (%), by Country
  • Figure 11. North America Drug Screening Share (%), by Country
  • Figure 12. Global Drug Screening: by Type k Units (2015-2020)
  • Figure 13. Global Drug Screening: by Sample Type k Units (2015-2020)
  • Figure 14. Global Drug Screening: by End User k Units (2015-2020)
  • Figure 15. South America Drug Screening Share (%), by Country
  • Figure 16. Asia Pacific Drug Screening Share (%), by Country
  • Figure 17. Europe Drug Screening Share (%), by Country
  • Figure 18. MEA Drug Screening Share (%), by Country
  • Figure 19. North America Drug Screening Share (%), by Country
  • Figure 20. Global Drug Screening: by Type USD/Units (2015-2020)
  • Figure 21. Global Drug Screening share by Players 2020 (%)
  • Figure 22. Global Drug Screening share by Players (Top 3) 2020(%)
  • Figure 23. Global Drug Screening share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Alere (United States) Revenue, Net Income and Gross profit
  • Figure 26. Alere (United States) Revenue: by Geography 2020
  • Figure 27. Thermo Fisher (United States) Revenue, Net Income and Gross profit
  • Figure 28. Thermo Fisher (United States) Revenue: by Geography 2020
  • Figure 29. Drägerwerk (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Drägerwerk (Germany) Revenue: by Geography 2020
  • Figure 31. OraSure (United States) Revenue, Net Income and Gross profit
  • Figure 32. OraSure (United States) Revenue: by Geography 2020
  • Figure 33. Alfa Scientific Designs (United States) Revenue, Net Income and Gross profit
  • Figure 34. Alfa Scientific Designs (United States) Revenue: by Geography 2020
  • Figure 35. Lifeloc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Lifeloc (United States) Revenue: by Geography 2020
  • Figure 37. MPD, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. MPD, Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Premier Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 40. Premier Biotech (United States) Revenue: by Geography 2020
  • Figure 41. Shimadzu (Japan), Revenue, Net Income and Gross profit
  • Figure 42. Shimadzu (Japan), Revenue: by Geography 2020
  • Figure 43. Siemens Healthineers (United States) Revenue, Net Income and Gross profit
  • Figure 44. Siemens Healthineers (United States) Revenue: by Geography 2020
  • Figure 45. Global Drug Screening: by Type USD Million (2021-2026)
  • Figure 46. Global Drug Screening: by Sample Type USD Million (2021-2026)
  • Figure 47. Global Drug Screening: by End User USD Million (2021-2026)
  • Figure 48. South America Drug Screening Share (%), by Country
  • Figure 49. Asia Pacific Drug Screening Share (%), by Country
  • Figure 50. Europe Drug Screening Share (%), by Country
  • Figure 51. MEA Drug Screening Share (%), by Country
  • Figure 52. North America Drug Screening Share (%), by Country
  • Figure 53. Global Drug Screening: by Type k Units (2021-2026)
  • Figure 54. Global Drug Screening: by Sample Type k Units (2021-2026)
  • Figure 55. Global Drug Screening: by End User k Units (2021-2026)
  • Figure 56. South America Drug Screening Share (%), by Country
  • Figure 57. Asia Pacific Drug Screening Share (%), by Country
  • Figure 58. Europe Drug Screening Share (%), by Country
  • Figure 59. MEA Drug Screening Share (%), by Country
  • Figure 60. North America Drug Screening Share (%), by Country
  • Figure 61. Global Drug Screening: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Alere (United States)
  • Thermo Fisher (United States)
  • Drägerwerk (Germany)
  • OraSure (United States)
  • Alfa Scientific Designs (United States)
  • Lifeloc (United States)
  • MPD, Inc. (United States)
  • Premier Biotech (United States)
  • Shimadzu (Japan),
  • Siemens Healthineers (United States)
Additional players considered in the study are as follows:
LabCorp (United States) , Quest Diagnostics (United States) , Omega Laboratories (United States) , Psyche medics (United States) , CRL (United States) , SureHire (Canada) , CannAmm (Canada)
Select User Access Type

Key Highlights of Report


Dec 2021 209 Pages 90 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and Regional Drug Screening Quantitative research analysis
Global and Regional Drug Screening Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Drug Screening market is expected to see a CAGR of 9.45% during projected year 2020 to 2026.
Top performing companies in the Global Drug Screening market are Alere (United States), Thermo Fisher (United States), Drägerwerk (Germany), OraSure (United States), Alfa Scientific Designs (United States), Lifeloc (United States), MPD, Inc. (United States), Premier Biotech (United States), Shimadzu (Japan), and Siemens Healthineers (United States), to name a few.
Breathalyzer is dominating segment of Drug Screening Market in 2020.

Know More About Global and Regional Drug Screening Report?

Have a Query? Click Here

Other Related Reports

Pharmacy Automation Systems Comprehensive Study by Type (Automated Medication Dispensing Systems, Decentralized Automated Dispensing Systems, Automated Packaging and Labeling Systems, Automated Table...
$ 3750
Propofol Comprehensive Study by Type (Local Anaesthesia, General Anesthesia), Application (Medical Uses, Other Uses), Route of Administration (Intravenous, Inhalational) Players and Region - Global M...
$ 3500
Pulmonary Function Testing Systems Comprehensive Study by Type (Portable PFT Systems, Complete PFT Systems), Application (Chronic Obstructive Pulmonary Disease, Asthma, Chronic Shortness of Breath, R...
$ 3750
Pet Dietary Supplement Comprehensive Study by Application (Residential, Commercial), Specialty (Urinary Tract Disease, Diabetes, Renal, Digestive Sensitivity, Oral Care, Other), Form (Soft Gel/Pills,...
$ 3450
Antibody Drug Conjugate Comprehensive Study by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), Conjugates (Small Molecules, Protein Toxin, Cytolytic Immunomodula...
$ 3750
Acne Medication Comprehensive Study by Type (Injection, Oral), Application (Hospital, Clinic) Players and Region - Global Market Outlook to 2028
$ 3500